Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified?

Review

. 2006 Apr;130(4):1357-62.

doi: 10.1053/j.gastro.2006.02.037.

Review

Robert J Fontana. Gastroenterology. 2006 Apr.

. 2006 Apr;130(4):1357-62.

doi: 10.1053/j.gastro.2006.02.037.

No abstract available

Comment on

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Berg T, et al. Gastroenterology. 2006 Apr;130(4):1086-97. doi: 10.1053/j.gastro.2006.02.015. Gastroenterology. 2006. PMID: 16618403 Clinical Trial.
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, Capanni M, Esperti F, Forte P, Guadagnino V, Mari T, Marino N, Milani S, Pasquazzi C, Rosina F, Tacconi D, Toti M, Zignego AL, Messerini L, Stroffolini T; Nonresponder Retreatment Group. Taliani G, et al. Gastroenterology. 2006 Apr;130(4):1098-106. doi: 10.1053/j.gastro.2006.02.016. Gastroenterology. 2006. PMID: 16618404 Clinical Trial.

[New data and recommendations of antiviral therapy of chronic hepatitis B and C].
Niederau C. Niederau C. Internist (Berl). 2008 Oct;49(10):1265-6, 1268-73. doi: 10.1007/s00108-008-2037-8. Internist (Berl). 2008. PMID: 18340426 Review. German.